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Background:  Patients suffering from diseased and injured organs may be treated with
transplanted organs. However, there is a severe shortage of donor organs which is worsening
yearly due to the aging population. Scientists in the field of tissue engineering apply the principles
of cell transplantation, materials science, and bioengineering to construct biological substitutes that
will restore and maintain normal function in diseased and injured tissues. Both therapeutic cloning
(nucleus from a donor cell is transferred into an enucleated oocyte), and parthenogenesis (oocyte
is activated and stimulated to divide), permit extraction of pluripotent embryonic stem cells, and
offer a potentially limitless source of cells for tissue engineering applications. The stem cell field is
also advancing rapidly, opening new options for therapy. The present article reviews recent
progress in tissue engineering and describes applications of these new technologies that may offer
novel therapies for patients with end-stage organ failure.
Introduction
The goal of tissue engineering is to repair organ patholo-
gies such as those acquired congenitally or by cancer,
trauma, infection, or inflammation. It is based upon the
foundations of cell transplantation and materials science.
Tissue can be engineered 1) in vivo- by stimulating the
body's own regeneration response with the appropriate
biomaterial, or 2) ex vivo- cells can be expanded in culture,
attached to a scaffold and then reimplanted into the host.
Cells may be heterologous (different species), allogeneic
(same species, different individual), or autologous (same
individual). Autologous cells are preferred because they
will not evoke an immunologic response and thus the del-
eterious side effects of immunosuppressive agents can be
avoided.
The ideal autologous cells can often be found within the
organ itself. These cells (committed precursors) may be
isolated, expanded and transplanted back into the same
patient, thus representing an autologous transplantation
resource. Previously, urothelial cells could be grown in the
laboratory setting with only limited expansion. Several
protocols were developed over the last 20 years which
identified the undifferentiated cells and kept them undif-
ferentiated during their growth phase [1-4]. Using such
cell culture methods it is now possible to expand a urothe-
lial strain from a single specimen which initially covered
a surface area of 1 cm2 to one that covers a surface area of
>4000 m2 (an area equivalent to one football field) within
8–14 weeks. These studies indicate the possibility of col-
lecting autologous bladder cells from human patients,
expanding them in culture, and returning them to the
human donor in sufficient quantities for reconstructive
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purposes [1,3-11]. Major advances have been achieved
within the past decade regarding possible expansion of
several primary human cell types with specific techniques
that employ autologous cells for clinical application.
While autologous cells are recognized as the ideal trans-
plantation resource, many patients with end-stage organ
disease are unable to yield sufficient cells for expansion
and transplantation. Furthermore, some primary autolo-
gous human cells cannot be expanded from particular
organs (i.e. pancreas, liver). Stem cells are envisioned as
being an alternate source of cells from which the desired
tissue can be derived. Human embryonic stem cells
(HESC) can be derived from discarded non transferred
embryos and have the advantage of being pluripotential
(the ability to differentiate into all tissues of the embryo)
and able to self-renew indefinitely. However, their clinical
application is limited because they represent an allogeneic
resource and thus their use would require high dose
immunosuppressant therapy.
New stem cell technologies such as somatic cell nuclear
transfer (therapeutic cloning) and parthenogenesis offer
an exciting alternative to create an inexhaustible supply of
ESC that can differentiate into all cell types of the embryo,
while not being rejected by the patient's immune system.
Although many tissues have been created with ESC, they
are not used clinically because of an inability to control
differentiation. Hence, their ability to form multiple tis-
sue types also becomes their limitation. New genomics
and bioinformatics technologies have and will continue
to offer new insights into the understanding of ESC
growth and differentiation and their application to engi-
neering tissues. In the near future, these new technologies
will allow for the generation of an unlimited supply of
any cell type in the body.
Stem cells
The political and ethical controversy surrounding stem
cells began in 1998 with the creation of HESC derived
from discarded, non-transferred human embryos[12]. The
HESC were isolated from the inner cell mass of a blasto-
cyst (5 days post-fertilization embryo) using an immuno-
surgical technique whereby the blastocyst was incubated
with antibodies specific to trophectoderm. Complement
proteins then resulted in lysis of the trophectoderm so
that the only surviving cells were the inner cell mass [13].
Given that some cells can not be expanded ex vivo, ESC can
potentially be the ideal resource for tissue engineering
because of two fundamental properties, 1) the ability to
self-renew indefinitely, and 2) the ability to differentiate
into all three germ layers.
With the current restrictions surrounding HESC work,
many proponents of stem cell research have sought to
modify the ban to incorporate the thousands of non-
transferred frozen embryos resulting from IVF to be used
for the creation of more HESC lines. A SART-RAND study
identified approximately 400,000 frozen embryos in stor-
age since the late 1970s [14]. However, only 2.8% of these
have been designated for research. Of the 11,000 embryos
designated for research, only 65% of these (n = 7,334) are
expected to survive the freeze/thaw process. From this,
25% are expected to develop to blastocyst stage (n = 1,
834). If one assumes a 15% efficiency rate for establish-
ment of a HESC line from blastocysts (as suggested by pre-
vious studies [12,15]), it may be estimated that
approximately 275 HESC could be created from excess
frozen embryos. However, the real number of HESC line
generated would actually be much lower since not all fro-
zen embryos allocated for research would be used to cre-
ate HESC lines. Furthermore, even if the maximum
possible number of HESC lines could be derived from
human frozen embryos, the clinical application of such
cells would be limited by the potential rejection from
another individual's immune system. New stem cell tech-
nologies (such as somatic cell nuclear transfer and parthe-
nogenesis) promise to overcome this limitation.
Somatic cell nuclear transfer (therapeutic cloning)
Somatic cell nuclear transfer (SCNT) entails the removal
of an oocyte nucleus followed by its replacement with a
nucleus derived from a somatic cell obtained from that
patient. Activation with chemicals or electric shock stimu-
lates cell division up to the blastocyst stage at which time
the inner cell mass is isolated and cultured, resulting in
ESC. This approach is distinct from reproductive cloning
because the blasotcyst is not transplanted back to the
uterus. Hence, development does not proceed beyond the
100 cell stage. This process also differs from fertilization
since no sperm is used in this process. The resulting ESC
are perfectly matched to the patients immune system and
no immunosuppressants would therefore be required to
prevent rejection.
While interest in the field of nuclear cloning remains high
since the birth of Dolly (1997), the first successful nuclear
transfer was actually reported over fifty years ago by Briggs
and King [16]. Cloned frogs, which were the first verte-
brates derived from nuclear transfer, were subsequently
reported by Gurdon in 1962 [17] although the nuclei
were derived from non-adult sources. Indeed, in just the
past six years alone important advances in nuclear cloning
technology have been reported – a pace of discovery that
betokens the relative immaturity of this research arena. In
fact Dolly was not the first cloned mammal to be pro-
duced from adult cells. Live lambs were produced in 1996
using nuclear transfer and differentiated epithelial cells,
although these were derived from embryonic discs [18].
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this described the first mammal to be derived from an
adult  somatic cell using nuclear transfer [19]. Subse-
quently, animals from several species have been grown
using nuclear transfer technology, including cattle [20],
goats [21,22], mice [23], and pigs [24-27].
A better understanding of the differences between repro-
ductive cloning and therapeutic cloning may help allevi-
ate some of the controversy surrounding these
technologies [28,29]. Banned in most countries for
human applications, reproductive cloning is used to gen-
erate an embryo that has the identical genetic material as
its cell source. Such an embryo could then be implanted
into the uterus of a female to give rise to a liveborn infant
that is a clone of the donor. In contrast, therapeutic clon-
ing is used to generate only ESC lines whose genetic mate-
rial is identical to that of its source. These autologous stem
cells have the potential to become almost any type of cell
in the adult body, and thus would be useful in tissue and
organ replacement applications [30]. Therefore, therapeu-
tic cloning (SCNT) may provide an alternative source of
transplantable cells. Figure 1 shows the strategy of com-
bining therapeutic cloning with tissue engineering to
develop tissues and organs. It has been estimated that
approximately 3,000 people die every day in USA of dis-
eases that could have been treated with stem cells-derived
tissues [31]. With current allogeneic tissue transplantation
protocols, rejection is a frequent complication because of
immunologic incompatibility and thus immunosuppres-
sive drugs are generally required to manage host-versus-
Strategy for therapeutic cloning and tissue engineering Figure 1
Strategy for therapeutic cloning and tissue engineeringJournal of Experimental & Clinical Assisted Reproduction 2004, 1:3 http://www.jexpclinassistreprod.com/content/1/1/3
Page 4 of 10
(page number not for citation purposes)
graft disease [30]. The use of transplantable tissue and
organs derived from therapeutic cloning could obviate
unwanted immune responses typically associated with
transplantation of non-autologous tissues [32].
While promising, somatic cell nuclear transfer technology
has certain limitations requiring further improvement
before it can be applied widely in clinical practice. Cur-
rently, the efficiency of the overall cloning process is quite
low as the majority of embryos derived from animal clon-
ing do not survive after implantation [33-35]. In practical
terms, multiple nuclear transfers must be performed in
order to produce one live offspring for animal cloning
applications. The potential for cloned embryos to grow
into live offspring ranges between <1 and 18% for sheep,
pigs, and mice [36]. However, greater success (~ 80%) has
been reported in cattle [37], a result which may in part be
due to availability of advanced laboratory technologies
specifically developed for this species for agricultural/
breeding purposes. To improve cloning efficiencies, fur-
ther improvements are required in the multiple complex
steps of nuclear transfer such as enucleation and recon-
struction, oocyte activation, and synchronization of cell
cycle between donor cells and recipient oocytes [38].
It must be noted that abnormalities have been found in
liveborn clones including macrosomia with an enlarged
placenta ("large-offspring syndrome") [39], respiratory
distress, defects of the kidney, liver, heart, and brain [40],
obesity [41], and premature death [42]. These may be
related to epigenetics of cloned cells which involve revers-
ible modifications of DNA, while the original DNA
(genetic) sequences remain intact. Faulty epigenetic mod-
ulation in clones may result from altered DNA methyla-
tion and/or histone modifications causing the overall
chromatin structure of somatic nuclei not to be repro-
grammed to an embryonic pattern of expression [30].
Reactivation of key embryonic genes at the blastocyst
stage usually does not occur in embryos cloned from
somatic cells, while embryos cloned from embryos con-
sistently express early embryonic genes[43,44]. Proper
epigenetic reprogramming to an embryonic state may
help to improve the cloning efficiency and reduce the inci-
dence of abnormal cloned cells.
Novel applications of somatic cell nuclear transfer 
(therapeutic cloning)
We applied principles of both tissue engineering and ther-
apeutic cloning in an effort to produce genetically identi-
cal renal tissue in an animal model (Bos taurus) [45].
Bovine skin fibroblasts from adult Holstein steers were
obtained by ear notch and single donor cells were isolated
and microinjected into the perivitelline space of donor
enucleated oocytes (nuclear transfer). The resulting blast-
ocysts were transferred to the uterus of progestin-synchro-
nized recipients permit further in vivo growth. After 12
weeks cloned renal cells were harvested, expanded in vitro,
then seeded onto biodegradable scaffolds. The constructs
(consisting of cells + scaffolds) were then implanted into
the subcutaneous space of the same steer from which the
cells were cloned to allow for tissue growth.
The kidney is a complex organ with multiple cell types
and a complex functional anatomy rendering it one of the
most difficult organs to reconstruct [46,47]. Previous
efforts in tissue engineering of the kidney have been
directed toward development of extracorporeal renal sup-
port systems made of biological and synthetic compo-
nents [48-54]. Although ex vivo renal replacement devices
are known to be life-sustaining, there are obvious benefits
for patients with end-stage kidney disease if such devices
could be implanted long-term without the need for an
extracorporeal perfusion circuit or immunosuppressive
drugs.
Cloned renal cells were seeded on scaffolds consisting of
three collagen-coated cylindrical polycarbonate mem-
branes (figure 2). The ends of the three membranes of
each scaffold were connected to catheters terminating in a
collecting reservoir. This created a renal neo-organ with a
mechanism for collecting the excreted urinary fluid (figure
3). Scaffolds with the collecting devices were transplanted
subcutaneously into the same steer from which the
genetic material originated and retrieved 12 weeks after
implantation.
Combining therapeutic cloning and tissue engineering to pro- duce kidney tissue, an illustration of the tissue-engineered  renal unit Figure 2
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Chemical analysis of the urine-like fluid (for urea nitro-
gen/creatinine levels, electrolyte levels, specific gravity,
and glucose concentration) revealed that the implanted
renal cells possessed filtration, reabsorption, and secre-
tory capabilities. Histological examination of the retrieved
implants revealed extensive vascularization and self-
organization of the cells into glomeruli- and tubule-like
structures. A clear continuity between glomeruli, tubules,
and the polycarbonate membrane was noted that allowed
the passage of urine into the collecting reservoir (figure 4).
Immunohistochemical analysis with kidney-specific anti-
bodies revealed the presence of renal proteins, and RT-
PCR analysis confirmed the transcription of renal specific
RNA in the cloned specimens. Western blot analysis con-
firmed the presence of elevated renal-specific protein
levels.
As previous studies have confirmed bovine clones harbor
mitochondrial DNA (mtDNA) of strictly oocyte origin
[55-57], the donor egg's mtDNA was thought to be a
potential source of immunologic incompatibility. Differ-
ences in mtDNA-encoded proteins expressed by cloned
cells could stimulate a T-cell response specific for mt-
DNA-encoded minor histocompatibility antigens when
cloned cells are implanted back into the original nuclear
donor [58]. We used nucleotide sequencing of the
Combining therapeutic cloning and tissue engineering to pro- duce kidney tissue, an illustration of the tissue-engineered  renal unit Figure 2
Combining therapeutic cloning and tissue engineering to pro-
duce kidney tissue, an illustration of the tissue-engineered 
renal unit.
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Renal unit seeded with cloned cells, three months after  implantation, showing the accumulation of urinelike fluid Figure 3
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mtDNA genomes of the clone and fibroblast nuclear
donor to identify potential antigens in the muscle con-
structs. Only two amino acid substitutions were noted to
distinguish cells from the clone and the nuclear donor.
Since peptide-binding motifs for bovine MHC class I mol-
ecules remain poorly understood, there is no reliable
method to predict the impact of these amino acid substi-
tutions on bovine histocompatibility.
Oocyte-derived mtDNA was also considered to be a
potential source of immunologic incompatibility in
cloned renal cells. Maternally transmitted minor histo-
compatibility antigens in mice have been shown to stim-
ulate both skin allograft rejection in vivo and cytotoxic T
lymphocytes expansion in vitro [58] that could prevent the
use of these cloned constructs in patients with chronic
rejection of major histocompatibility-matched human
renal transplants [59,60]. We tested for a possible T-cell
response to the cloned renal devices using delayed-type
hypersensitivity testing in vivo and Elispot analysis of
interferon-gamma secreting T-cells in vitro. Both analyses
revealed that the cloned renal cells showed no evidence of
T-cell response, suggesting that rejection will not necessar-
ily occur in the presence of oocyte-derived mtDNA (figure
5). This finding may represent a step forward in overcom-
ing the histocompatibility problem of stem cell therapy
[47].
These studies demonstrated that cells derived from
nuclear transfer can be successfully harvested, expanded
in culture, and transplanted in vivo with the use of biode-
gradable scaffolds on which the single suspended cells can
organize into tissue structures that are genetically identical
to that of the host. These studies were the first demonstra-
tion of the use of therapeutic cloning for regeneration of
tissues  in vivo. Others in the field have created mouse
SCNT derived c-kit-positive stem cells to restore infarcted
myocardium [61], dopaminergic neurons to correct the
phenotype of a mouse model of Parkinson disease [62].
The first HESC line derived from SCNT was created in Feb-
ruary, 2004 [63].
Parthenogenesis
Parthenogenesis (<Gr. "virgin birth") is production of off-
spring by a female with no genetic contribution from a
male and without meiotic chromosome reduction. The
process is common reproductive strategy among insects
such as aphids, flies, ants, and honeybees, but is also
known to occur in vertebrates including lizards, snakes,
fish, birds, and amphibians. The first demonstration of
artificially-stimulated parthenogenesis in vitro was made
by Jacques Loeb (1899), who was able to activate oocytes
from sea urchins and frogs by pricking them with a needle
or by changing the ambient salt concentration. Pincus
(1939) demonstrated parthenogenetic activation of mam-
malian eggs using temperature and chemical stimuli. Thus
far, parthenogenetic activation of eggs has been studied in
a variety of mammals including mice, goats, cows, mon-
keys, and humans. Plachot et al. described parthenogene-
sis in humans by examining 800 human oocytes and
showed that 12 activated parthenogenetically and four
underwent normal cleavage[64]. Although there have
been no reports of naturally-occurring human parthe-
notes, a human parthenogenetic chimera has been
described [65]. The juvenile patient presented with devel-
opmental delay, apparent sex reversal, and entirely par-
thenogenetic blood leukocytes. This finding confirmed
the viability of chimeras in higher mammals as presaged
by successful murine experiments over the previous two
decades (see below).
There is no confirmed example of de novo mammalian
parthenogenetic reproduction, but mammalian oocytes
can be artificially induced to undergo parthenogenesis in
vitro  by a two-step protocol involving electroporation
and/or treatment with a chemical agent (ionomycin, eth-
anol, or inositol 1,4,5-triphosphate) to elevate Ca2+ levels
transiently, followed by application of an inhibitor of
protein synthesis (cycloheximide) or protein phosphor-
ylation (6-dimethylaminopurine). Success rates and via-
bility appear to be organism dependent. Mouse
parthenotes are capable of developing beyond the post-
implantation stage in vivo [66,67]; porcine parthenotes
Clear unidirectional continuity between the mature glomer- uli, their tubules, and the polycarbonate membrane Figure 4
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have developed up to post-activation day 29 (limb bud
stage, past the early heart beating stage); rabbit parthe-
notes until day 10–11 [68]; primates (Callithrix jacchus)
have only been shown to implant [69]. The reason for this
arrested development is believed to be due to genetic
imprinting. In normal zygotes maternal and paternal hap-
loid genomes are epigenetically distinct, and both sets are
required for successful development [70,71]. Indeed,
unstable chromosome modifications in the form of DNA
methylation or histone modification are distinctly differ-
ent in human sperm, compared to eggs. Therefore each
gamete carries unique patterns of gene expression into the
embryo. Since all genetic material in parthenotes is of
maternal origin, there is no paternal imprinting compo-
nent and this prevents proper development of extraem-
bryonic tissues whose expression is regulated by the male
genome [72]. In most mammals – including primates –
oocytes are arrested at metaphase II just before ovulation.
Cytogenetic microscopy shows the presence of a 2n polar
body under the zona pellucida and a 2n protonucleus in
the cytoplasm. After chemical activation to mimic the
effects of sperm penetration on changes in cellular Ca2+
gradient, the cell fails to complete meiosis II. Instead, the
second polar body is never extruded, resulting in a diploid
protonucleus derived from two sets of sister chromatids.
These chromatids then begin to undergo mitosis resulting
in a parthenote manifesting uniparental disomy.
Although the derivation of embryonic-like stem cells from
oocytes (parthenogenetic stem cells, PSC) is relatively
inefficient (perhaps due to complexities of genomic
Elispot analyses of the frequencies of T-cells that secrete IFN-gamma after primary and secondary stimulation with allogeneic  renal cells, cloned renal cells, or nuclear donor fibroblasts Figure 5
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imprinting), when they are differentiated into adult tis-
sues, they appear fully functional.
In spite of non-viability of monkey parthenotes, the
extracted stem cells seem to assume the morphology and
functional behavior of HESC and express appropriate ESC
markers. They have embryonic-like replicative ability and
have been propagated in vitro in an undifferentiated state
for up to 14 months. In vitro, they have been differentiated
into cardiomyocyte-like cells, smooth muscle, beating cil-
iated epithelia, adipocytes, several types of epithelial cells,
as well as dopaminergic and serotoninergic neurons.
Almost all of these neurons express TUJ1 (beta-tubulin
III), and up to 25% of the TUJ1+ cells co-express tyrosine-
hydroxylase. This latter enzyme marker is considered diag-
nostic for catecholaminergic neurons (dopamine, nore-
pinephrine, and epinephrine [73]). Furthermore, HPLC
analysis of culture media following a depolarizing KCl-
buffer identifies the release of the neurotransmitters
dopamine and serotonin from the cells. Ater two weeks of
differentiation, about half of the cells demonstrate neuro-
nal morphology and begin to express voltage-dependent
sodium channels that can be blocked by tetrodotoxin.
These observations are recapitulated in vivo, since injec-
tion of monkey PSC into immunocompromised mice
induces formation of benign teratomas containing tissue
derivatives from all three germ layers (ectoderm, endo-
derm and mesoderm) including cartilage, muscle, bone,
neurons, skin, hair follicles, and intestinal epithelia
[74,75]. Of particular note is the apparent tendency of
these cells to differentiate into neuronal tissues, as has
been noted by chimera studies [67]. The reasons for this
underlying preference are not well understood although
one possible explanation is that it is a consequence of
purely maternal genomic imprinting, reflecting a lack of
epigenetic balance that would be conferred by paternally-
imprinted genes.
To be sure, parthenotes are not free from ethical contro-
versy and are viewed by some in society as artificial enti-
ties that in some sense represent 'tampering with nature.'
Since a parthenote is analogous to a mature ovarian
teratoma (a spontaneous in vivo tumorigenic event) the de
facto acceptance of experiments using teratoma tumor tis-
sue lends some legitimacy to experimentation on parthe-
notes. These contradictions await reconciliation in a
comprehensive ethical framework.
Stem cell genomics
The pluripotentiality of stem cells is also their limitation,
and explains why they are not used clinically today.
Although ESC can be differentiated into skin, neurons,
blood, cardiac cells, cartilage, endothelial cells, muscle,
hepatocytes, and pancreatic cells, the efficiency can be
quite limited for certain cell types. Another difficulty is
studying the quality of differentiation: are the neurons
derived from stem cells bona fide neurons, or merely neu-
ronal-like cells? To address this question we developed
high throughput methodologies using microarrays to
evaluate new stem cell derivatives [76]. We differentiated
HESC into retinal pigmented epithelial cells (RPE) (the
site of lesions in macular degeneration and retinitis pig-
mentosa) and used microarrays to identify their genetic
signature. We then compared their gene signature to those
derived from two established RPE cell lines (one of which
has been successfully used clinically). A bronchial epithe-
lial cell line served as a negative control and a freshly iso-
lated human RPE served as a positive control. We
demonstrated similarity between our HESC derived RPE
and the freshly isolated RPE. The bronchial epithelial and
two other established RPE lines were less similar. Interest-
ingly, the data set that represented the genes common to
freshly isolated RPE and HESC derived RPE (but not in the
two established lines), contained many retinal specific
genes. This finding provided further support of the bene-
fits of HESC: the ability to generate a limitless number of
HESC with the potential to differentiate along specific lin-
eages to allow creation of RPE cells in quantities necessary
for clinical transplantation. The next step would be to cou-
ple this technology to ESC derived from SCNT (or parthe-
nogenesis) to create the ideal treatment for macular
degeneration and retinitis pigmentosa.
Another technology currently under development at our
institution is "genomics guided tissue engineering." Here
we perform microarrays periodically during stem cell dif-
ferentiation. For example, microarrays are performed on
undifferentiated monkey PSC, PSC derived neural precur-
sors (PSC-NP), and NP that were further differentiated for
8 days (PSC-neurons). We have identified numerous tar-
gets such as receptors and ligands present at each of these
distinct time points, and are modifying our culture system
in order to improve the quality and quantity of differenti-
ation. Furthermore, we are comparing the gene expression
profiles of PSC derived neurons to gene expression pro-
files of reference neurons. Not only will this provide new
insight into the type of neurons that may be generated,
but it offers clues into what our stem cell derived neurons
might be lacking. We can then go back to the culture sys-
tem and try to target these specific genes/signaling
pathways.
Further study of stem cell genomics will give additional
insight into pluripotentiality. An understanding of
pluripotentiality might allow for a somatic cell to be de-
differentiated into an intermediate stage, which could
then be expanded, differentiated and transplanted back
into the patient. We are presently characterizing the
genetic signature of pluripoteniality by analyzing geneJournal of Experimental & Clinical Assisted Reproduction 2004, 1:3 http://www.jexpclinassistreprod.com/content/1/1/3
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expression among primate stem cells derived from a vari-
ety of methods (IVF, parthenogenesis, and adult stem
cells). By identifying "stemness" genes by comparing
undifferentiated stem cells to their differentiated counter-
part, and comparing this to stem cells of different origins,
a core set of pluripotential target genes may be mapped.
Of particular interest are the 1,075 genes that are similarly
down-regulated in IVF derived human ESC and monkey
PSC. Furthermore, we have detected paternally imprinted
genes in our HESC but not in our PSC data sets. From this
we conclude that paternal imprinting might not be neces-
sary for pluriopotentiality.
Conclusion
Our systems biology approach incorporates the fields of
genomics, cell biology, nuclear transfer, and materials sci-
ence, and utilizes personnel who have mastered the
techniques of bioinformatics, cell harvest, culture, expan-
sion, transplantation, as well as polymer design essential
for the successful application of these technologies. Exper-
imental efforts are currently underway involving virtually
every type of tissue and organ of the human body. Various
tissues are at different stages of development with some
already being used clinically, a few in pre-clinical trials,
and some in the discovery stage. Recent progress suggests
that engineered tissues may have an expanded clinical
applicability in the future and may represent a viable ther-
apeutic option for those who require tissue replacement
or repair.
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